epaminurad
Jump to navigation
Jump to search
Indications
- effective at reducing serum uric acid in patients with gout
* 12 week phase 2b clinical trial[1]
Dosage
Adverse effects
- well tolerated
Mechanism of action
- inhibits URAT1
More general terms
References
- ↑ 1.0 1.1 Jun JB, Lee HS, Kim SH et al Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study. Arthritis Res Ther. 2025 May 26;27(1):113. PMID: https://pubmed.ncbi.nlm.nih.gov/40420308 PMCID: PMC12105222 Free PMC article. Clinical Trial.